DE602005008065D1 - Von phosphatidylinosit-(pi-)3-kinase und deren verwendung bei der behandlung von krebs - Google Patents
Von phosphatidylinosit-(pi-)3-kinase und deren verwendung bei der behandlung von krebsInfo
- Publication number
- DE602005008065D1 DE602005008065D1 DE602005008065T DE602005008065T DE602005008065D1 DE 602005008065 D1 DE602005008065 D1 DE 602005008065D1 DE 602005008065 T DE602005008065 T DE 602005008065T DE 602005008065 T DE602005008065 T DE 602005008065T DE 602005008065 D1 DE602005008065 D1 DE 602005008065D1
- Authority
- DE
- Germany
- Prior art keywords
- sup
- phosphatidylinosite
- kinase
- cancer
- treatment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 206010028980 Neoplasm Diseases 0.000 title 1
- 201000011510 cancer Diseases 0.000 title 1
- 238000004519 manufacturing process Methods 0.000 abstract 2
- 230000001028 anti-proliverative effect Effects 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 229940083082 pyrimidine derivative acting on arteriolar smooth muscle Drugs 0.000 abstract 1
- 150000003230 pyrimidines Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/32—One oxygen, sulfur or nitrogen atom
- C07D239/42—One nitrogen atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0415365.6A GB0415365D0 (en) | 2004-07-09 | 2004-07-09 | Pyrimidine derivatives |
| PCT/GB2005/002664 WO2006005914A1 (en) | 2004-07-09 | 2005-07-07 | 2, 4, 6-trisubstituted pyrimidines as phosphotidylinositol (pi) 3-kinase inhibitors and their use in the treatment of cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DE602005008065D1 true DE602005008065D1 (de) | 2008-08-21 |
Family
ID=32865683
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE602005008065T Expired - Fee Related DE602005008065D1 (de) | 2004-07-09 | 2005-07-07 | Von phosphatidylinosit-(pi-)3-kinase und deren verwendung bei der behandlung von krebs |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US20080058332A1 (de) |
| EP (1) | EP1768978B1 (de) |
| JP (1) | JP2008505875A (de) |
| CN (1) | CN101014590A (de) |
| AT (1) | ATE400570T1 (de) |
| AU (1) | AU2005261551A1 (de) |
| BR (1) | BRPI0513058A (de) |
| CA (1) | CA2571748A1 (de) |
| DE (1) | DE602005008065D1 (de) |
| GB (1) | GB0415365D0 (de) |
| IL (1) | IL180136A0 (de) |
| MX (1) | MX2007000119A (de) |
| NO (1) | NO20070655L (de) |
| WO (1) | WO2006005914A1 (de) |
| ZA (1) | ZA200700054B (de) |
Families Citing this family (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MXPA05005477A (es) | 2002-11-21 | 2005-07-25 | Chiron Corp | Pirimidinas 2,4,6-trisustituidas como inhibidores de fosfotidilinositol (pi) 3-cinasa y su uso en el tratamiento del cancer. |
| GB0415364D0 (en) | 2004-07-09 | 2004-08-11 | Astrazeneca Ab | Pyrimidine derivatives |
| GB0520657D0 (en) | 2005-10-11 | 2005-11-16 | Ludwig Inst Cancer Res | Pharmaceutical compounds |
| GB0525080D0 (en) * | 2005-12-09 | 2006-01-18 | Astrazeneca Ab | Pyrimidine derivatives |
| GB0525081D0 (en) * | 2005-12-09 | 2006-01-18 | Astrazeneca Ab | Pyrimidine derivatives |
| GB0525083D0 (en) * | 2005-12-09 | 2006-01-18 | Astrazeneca Ab | Pyrimidine derivatives |
| JO2660B1 (en) | 2006-01-20 | 2012-06-17 | نوفارتيس ايه جي | Pi-3 inhibitors and methods of use |
| WO2007140263A2 (en) | 2006-05-26 | 2007-12-06 | University Of Louisville Research Foundation, Inc. | Macrophage migration inhibitory factor antagonists and methods of using same |
| JP5534811B2 (ja) * | 2006-08-24 | 2014-07-02 | アストラゼネカ アクチボラグ | 増殖性疾患の治療に有用なモルホリノピリミジン誘導体 |
| WO2008032041A1 (en) * | 2006-09-14 | 2008-03-20 | Astrazeneca Ab | Pyrimidine derivatives having inhibitory activity against pi3k enzymes |
| ATE551334T1 (de) * | 2007-02-06 | 2012-04-15 | Novartis Ag | Pi3-kinase-hemmer und verfahren zu ihrer verwendung |
| US8138183B2 (en) * | 2007-07-09 | 2012-03-20 | Astrazeneca Ab | Morpholino pyrimidine derivatives used in diseases linked to mTOR kinase and/or PI3K |
| US20100261723A1 (en) * | 2007-07-09 | 2010-10-14 | Astrazeneca Ab | Trisubstituted pyrimidine derivatives for the treatment of proliferative diseases |
| WO2010120994A2 (en) * | 2009-04-17 | 2010-10-21 | Wyeth Llc | Ureidoaryl-and carbamoylaryl-morpholino- pyrimidine compounds, their use as mtor kinase and pi3 kinase inhibitors, and their synthesis |
| JP5680638B2 (ja) | 2009-07-02 | 2015-03-04 | サノフイ | 新規な（６−オキソ−１，６−ジヒドロピリミジン−２−イル）アミド誘導体、この調製およびａｋｔ（ｐｋｂ）リン酸化インヒビターとしてのこの医薬的な使用 |
| WO2011038234A2 (en) | 2009-09-24 | 2011-03-31 | University Of Louisville Research Foundation, Inc. | Novel iodo pyrimidine derivatives useful for the treatment of macrophage migration inhibitory factor (mif)-implicated diseases and conditions |
| KR101426180B1 (ko) | 2009-11-02 | 2014-07-31 | 화이자 인코포레이티드 | 디옥사-비시클로［3.2.1］옥탄-2,3,4-트리올 유도체 |
| WO2011146824A1 (en) | 2010-05-20 | 2011-11-24 | University Of Louisville Research Foundation, Inc. | Methods and compositions for modulating ocular damage |
| SA111320519B1 (ar) | 2010-06-11 | 2014-07-02 | Astrazeneca Ab | مركبات بيريميدينيل للاستخدام كمثبطات atr |
| TWI547493B (zh) | 2011-09-27 | 2016-09-01 | 諾華公司 | 作為突變ｉｄｈ之抑制劑之３－嘧啶－４－基－唑啶－２－酮 |
| UY34632A (es) | 2012-02-24 | 2013-05-31 | Novartis Ag | Compuestos de oxazolidin- 2- ona y usos de los mismos |
| US9296733B2 (en) | 2012-11-12 | 2016-03-29 | Novartis Ag | Oxazolidin-2-one-pyrimidine derivative and use thereof for the treatment of conditions, diseases and disorders dependent upon PI3 kinases |
| ES2665619T3 (es) | 2013-03-14 | 2018-04-26 | Novartis Ag | 3-Pirimidin-4-il-oxazolidin-2-onas como inhibidores de IDH mutante |
| US9242969B2 (en) | 2013-03-14 | 2016-01-26 | Novartis Ag | Biaryl amide compounds as kinase inhibitors |
| CN104151256B (zh) * | 2014-08-14 | 2016-08-24 | 西安交通大学 | 二取代苯甲酰胺类化合物及其合成方法和应用 |
| UY36294A (es) | 2014-09-12 | 2016-04-29 | Novartis Ag | Compuestos y composiciones como inhibidores de quinasa |
| CN107793365B (zh) * | 2016-08-31 | 2021-08-17 | 上海微创医疗器械（集团）有限公司 | 一种化合物及其制备方法和用途 |
| AU2017329090B9 (en) | 2016-09-19 | 2019-09-05 | Novartis Ag | Therapeutic combinations comprising a RAF inhibitor and a ERK inhibitor |
| TWI798218B (zh) | 2017-05-02 | 2023-04-11 | 瑞士商諾華公司 | 組合療法 |
| MX2021013817A (es) | 2019-05-13 | 2021-12-14 | Novartis Ag | Nuevas formas cristalinas de n-(3-(2-(2-hidroxietoxi)-6-morfolinop iridin-4-il)-4-metilfenil)-2-(trifluorometil)isonicotinamida como inhibidores de raf para el tratamiento del cancer. |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE19836697A1 (de) * | 1998-08-13 | 2000-02-17 | Hoechst Marion Roussel De Gmbh | Substituierte 4-Amino-2-aryl-pyrimidine, ihre Herstellung, ihre Verwendung und sie enthaltende pharmazeutische Präparate |
| KR100774855B1 (ko) * | 2000-04-27 | 2007-11-08 | 아스텔라스세이야쿠 가부시키가이샤 | 축합 헤테로아릴 유도체 |
-
2004
- 2004-07-09 GB GBGB0415365.6A patent/GB0415365D0/en not_active Ceased
-
2005
- 2005-07-07 CN CNA2005800297498A patent/CN101014590A/zh active Pending
- 2005-07-07 AU AU2005261551A patent/AU2005261551A1/en not_active Abandoned
- 2005-07-07 EP EP05758844A patent/EP1768978B1/de not_active Expired - Lifetime
- 2005-07-07 US US11/630,677 patent/US20080058332A1/en not_active Abandoned
- 2005-07-07 BR BRPI0513058-1A patent/BRPI0513058A/pt not_active Application Discontinuation
- 2005-07-07 DE DE602005008065T patent/DE602005008065D1/de not_active Expired - Fee Related
- 2005-07-07 MX MX2007000119A patent/MX2007000119A/es not_active Application Discontinuation
- 2005-07-07 JP JP2007519882A patent/JP2008505875A/ja active Pending
- 2005-07-07 WO PCT/GB2005/002664 patent/WO2006005914A1/en not_active Ceased
- 2005-07-07 CA CA002571748A patent/CA2571748A1/en not_active Abandoned
- 2005-07-07 AT AT05758844T patent/ATE400570T1/de not_active IP Right Cessation
-
2006
- 2006-12-17 IL IL180136A patent/IL180136A0/en unknown
-
2007
- 2007-01-02 ZA ZA200700054A patent/ZA200700054B/en unknown
- 2007-02-05 NO NO20070655A patent/NO20070655L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| CN101014590A (zh) | 2007-08-08 |
| NO20070655L (no) | 2007-03-21 |
| GB0415365D0 (en) | 2004-08-11 |
| ATE400570T1 (de) | 2008-07-15 |
| EP1768978B1 (de) | 2008-07-09 |
| EP1768978A1 (de) | 2007-04-04 |
| BRPI0513058A (pt) | 2008-04-22 |
| AU2005261551A1 (en) | 2006-01-19 |
| IL180136A0 (en) | 2007-06-03 |
| ZA200700054B (en) | 2008-05-28 |
| US20080058332A1 (en) | 2008-03-06 |
| WO2006005914A1 (en) | 2006-01-19 |
| JP2008505875A (ja) | 2008-02-28 |
| CA2571748A1 (en) | 2006-01-19 |
| MX2007000119A (es) | 2007-03-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE602005008065D1 (de) | Von phosphatidylinosit-(pi-)3-kinase und deren verwendung bei der behandlung von krebs | |
| DE602004011199D1 (de) | 5-phenylthiazolderivate und deren verwendung als p13-kinase-inhibitoren | |
| BRPI0409198A (pt) | derivados quinolin-2-ona para o tratamento de doenças de vias aéreas | |
| SE0300480D0 (sv) | Novel compounds | |
| ATE353888T1 (de) | Chinazolinderivate | |
| ATE433447T1 (de) | Pyrimiidinverbindungen | |
| TW200519106A (en) | Organic compounds | |
| SE0104140D0 (sv) | Novel Compounds | |
| CY1107683T1 (el) | Ενωσεις που επηρεαζουν τη γλυκοκιναση | |
| BRPI0418251C1 (pt) | fosfonatos, monofosfonamidatos, bisfosfonamidatos, e, composição farmacêutica os compreendendo | |
| SE0202539D0 (sv) | Compounds | |
| ATE500245T1 (de) | Pyridonamidderivate als fokale adhäsionskinase (fak)-inhibitoren und ihre verwendung zur behandlung von krebs | |
| TW200801003A (en) | Novel compounds | |
| CY1112960T1 (el) | Παραγωγα ουριας, μεθοδοι για την παρασκευη τους και χρησεις αυτων | |
| SE0302139D0 (sv) | Novel compounds | |
| DE60215178D1 (de) | Quinolin-derivate und ihre verwendung als inhibitoren der tyrosine kinase | |
| TW200618801A (en) | Pyrimidine derivatives | |
| GEP20135959B (en) | Aryl piperazine and their usage as alpha2c antagonists | |
| TW200738659A (en) | Novel compounds | |
| ATE521609T1 (de) | Aminothiazolylpyrimidinderivate und ihre verwendung bei der behandlung von krebs | |
| ATE499372T1 (de) | Azabenzimidalzolderivate, ihre herstellung und ihre verwendung als antikrebsmittel | |
| SE0303280D0 (sv) | Novel compounds | |
| TW200731975A (en) | Novel combinations of medicaments for the treatment of respiratory diseases | |
| ATE482955T1 (de) | Azabicyclooctan-3-onderivate und deren verwendung | |
| MX2007007027A (es) | Derivados piperazinilpiridina como agentes anti-obesidad. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 8364 | No opposition during term of opposition | ||
| 8339 | Ceased/non-payment of the annual fee |